Halofuginone has a beneficial effect on gentamicin-induced acute nephrotoxicity in rats

Drug and Chemical Toxicology

Volumn 32, Issue 4, 2009, Pages 312-318

  Karakoyun, Berna ^a   Yuksel, Meral ^a   Turan, Pinar ^a   Arbak, Serap ^a   Alican, Inci ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

Gentamicin; Halofuginone; Nephrotoxicity

Indexed keywords

GENTAMICIN; GLUTATHIONE; HALOFUGINONE; MALONALDEHYDE; MYELOPEROXIDASE; SODIUM CHLORIDE; ANTIOXIDANT; CHLORIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIPERIDINE DERIVATIVE; PLANT EXTRACT; QUINAZOLINONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CHEMOLUMINESCENCE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; KIDNEY FUNCTION TEST; MALE; NEPHROTOXICITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; UREA NITROGEN BLOOD LEVEL; URINALYSIS; ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; DRUG INTERACTION; KIDNEY; KIDNEY FAILURE; KIDNEY TUBULE; METABOLISM; OXIDATIVE STRESS;

ANIMALIA; RATTUS;

ANIMALS; ANTIOXIDANTS; CHLORIDES; DRUG INTERACTIONS; FEMALE; GENTAMICINS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; KIDNEY FAILURE; KIDNEY FUNCTION TESTS; KIDNEY TUBULES; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PIPERIDINES; PLANT EXTRACTS; QUINAZOLINONES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 74049165071     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.1080/01480540902976911     Document Type: Article

References (30)

1. Abramovitch R, Dafni H, Neman M, Nagler A, Pines M. (1999). Inhibition of neovascularization and tumor growth and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia 1:321-329.
2. Aykac G, Uysal M, Yalcin AS, Kocak-Toker N, Sivas A, Oz H. (1985). The effect of chronic ethanol ingestion on hepatic lipid peroxide, glutathione peroxidase, and glutathione transferase in rats. Toxicology 36:71-76.
3. Baliga R, Ueda N, Walker PD, Shah SV. (1999). Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 31:971-997.
4. Bradley PP, Preibat D, Christerser RD, Rothstein G. (1982). Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78:206-209.
5. Bruck R, Genina O, Aeed H, Alexiev R, Nagler A, Avni Y, Pines M. (2001). Halofuginone to prevent and treat thioacetamideinduced liver fibrosis in rats. Hepatology 33:379-386.
6. Casini A, Ferrali M, Pompella AS, Maellaro E, Comporti M. (1986). Lipid peroxidation and cellular damage in extrahepatic tissues of bromobenzene- intoxicated mice. Am J Pathol 123:520-531.
7. Conner EM, Grisham MB. (1996). Inflammation, free radicals, and antioxidants. Nutrition 12:274-277.
8. Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Di Paola R, Britti D, et al. (2002). A role for superoxide in gentamicin-mediated nephropathy in rats. Eur J Pharmacol 450:67-76.
9. Davies GR, Simmonds NJ, Stevens TR, Grandison A, Blake DR, Rampton DS. (1992). Mucosal reactive oxygen metabolite production in duodenal ulcer disease. Gut 33:1467-1472.
10. Eisenberg JM, Koffer H, Glick HA, Connell ML, Loss LE, Talbot GH, et al. (1987). What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 107:900-909.
11. Elkin M, Ariel I, Miao HQ, Nagler A, Pines M, de Groot N, et al. (1999a). Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res 59:4111-4118.
12. Elkin M, Reich R, Nagler A, Aingorn E, Pines M, de Groot N, et al. (1999b). Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin Cancer Res 5:1982-1988. (Pubitemid 29399247)
13. Farag MM, Mikhail M, Schata R, Abdel-Meguid E, Abdel-Tawab S. (1996). Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium. Clin Sci (Lond) 91:187-191.
14. Granot I, Bartov I, Plavnik I, Wax E, Hurwitz S, Pines M. (1991). Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone. Poult Sci 70:1559-1563.
15. Granot I, Halevy O, Hurwitz S, Pines M. (1993). Halofuginone: an inhibitor of collagen type I synthesis. Biochim Biophys Acta 1156:107-112.
16. Halevy O, Nagler A, Levi-Schaffer F, Genina O, Pines M. (1996). Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Biochem Pharmacol 52:1057-1063.
17. Karatas A, Paksoy M, Erzin Y, Carkman S, Gonenc M, Ayan F, et al. (2008). The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of pancreatic fibrosis in an experimental model of severe hyperstimulation and obstruction pancreatitis. J Surg Res 148:7-12.
18. Levi-Schaffer F, Nagler A, Slavin S, Knopov V, Pines M. (1996). Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone. J Invest Dermatol 106:84-88. (Pubitemid 26053386)
19. Nagler A, Firman N, Feferman R, Cotev S, Pines M, Shoshan S. (1996). Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Respir Crit Care Med 154:1082-1086.
20. Nagler A, Katz A, Aingorn H, Miao HQ, Condiotti R, Genina O, et al. (1997a). Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone. Kidney Int 52:1561-1569.
21. Nagler A, Miao HQ, Aingorn H, Pines M, Genina O, Vlodavsky I. (1997b). Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone. Arterioscler Thromb Vasc Biol 17:194-202.
22. Nyska M, Nyska A, Rivlin E, Porat S, Pines M, Shoshan S, et al. (1996). Topically applied halofuginone, an inhibitor of collagen type I transcription, reduces peritendinous fibrous adhesions following surgery. Connect Tissue Res 34:97-103.
23. Pedraza-Chaverri J, Gonzalez-Orozco AE, Maldonado PD, Barrera D, Medina-Campos ON, Hernandez-Pando R. (2003). Dialyl disulfide ameliorates gentamicin-induced oxidative stress and nephropathy in rats. Eur J Pharmacol 473:71-78.
24. Pines M, Knopov V, Genina O, Lavelin I, Nagler A. (1997). Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine- induced liver cirrhosis. J Hepatol 27:391-398.
25. Pines M, Nagler A. (1998). Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 30:445-450. (Pubitemid 28102819)
26. Priuska EM, Schacht J. (1995). Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. Biochem Pharmacol 50:1749-1752.
27. Samadian T, Dehpour AR, Amini S, Nouhnejad P. (1993). Inhibition of gentamicin-induced nephrotoxicity by lithium in rat. Histol Histopathol 8:139-147.
28. Taras D, Blanc JF, Rullier A, Dugot-Senant N, Laurendeau I, Bieche I, et al. (2006). Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition. Neoplasia 8:312-318.
29. Walker PD, Shah SV. (1988). Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats. J Clin Invest 81:334-341.
30. Yanagida C, Ito K, Komiya I, Horie T. (2004). Protective effect of fosfomycin on gentamicin-induced lipid peroxidation of rat renal tissue. Chem Biol Interact 148:139-147.